Press Releases

Press Releases

Date Title & Summary Additional Formats
09/07/21
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting compounds designed to transform the standard of care for prevention and treatment of serious diseases, today announced that Jeffrey Stein, Ph.D., president and
09/02/21
Cidara Therapeutics to Host Research and Development Day
Virtual event will highlight the broad potential of the Cloudbreak ® platform and the commercial potential for rezafungin Clinical thought leaders will highlight the risks of invasive fungal infections in cancer patients, and the unmet medical need in respiratory viral diseases Webinar to be held
09/01/21
Cidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary
Appointments add two biotech industry veterans each with over two decades of experience to Company’s management team SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard
08/17/21
Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Top-line data anticipated in late 2021 Single Phase 3 trial serves as basis for global regulatory filings SAN DIEGO and CAMBRIDGE, England, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Mundipharma today announced that the companies have completed recruitment of the
08/12/21
Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the second
08/05/21
Cidara Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President
07/27/21
Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress
SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present clinical and
07/12/21
Cidara Therapeutics Presents New Analyses from Multiple Rezafungin Studies at ECCMID 2021
Oral presentation shows clinical data demonstrating clearance of infection in initial days of treatment of candidemia following one dose of rezafungin compared to multiple daily doses of standard of care Three additional presentations to highlight areas of unmet medical needs to improve treatment
07/07/21
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compensation Committee of
07/01/21
Cidara Therapeutics Provides Leadership Update
SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that James (Jamie) Levine has